A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping

Inclusion Criteria: * 1\. Histopathological diagnosis confirmed as diffuse large B-cell lymphoma, with CD20 positivity; * 2\. Simultaneous expression of MYC and BCL2, according to the WHO standard for immunohistochemistry: MYC ≥ 40%, BCL2 ≥ 50% * 3\. Age ≥ 18 years old and ≤ 75 years old; * 4\. ECOG performance status score of 0, 1, or 2; * 5\. International Prognostic Index (IPI) \> 1 * 6\. No history of malignant tumor; no concurrent occurrence of other tumors; * 7\. Patients with an expected lifespan of at least 6 months, as determined by the researcher; * 8\. The patient or their legal representative must provide written informed consent before undergoing any special examinations or procedures in the study. Exclusion Criteria: * 1\. Have previously received systemic or local treatments, including chemotherapy; * 2\. Have previously undergone autologous stem cell transplantation; * 3\. Previously had a history of other malignant tumors, excluding basal cell carcinoma and cervical carcinoma in situ; * 4\. Accompanied by uncontrolled cardiovascular and cerebrovascular diseases, coagulation disorders, connective tissue diseases, severe infectious diseases, etc; * 5\. Primary central nervous system lymphoma; * 6\. Left ventricular ejection fraction (LVEF) is less than or equal to 50%; * 7\. Laboratory test values during screening: (unless caused by lymphoma); A. Neutrophil count \<1.5\*10\^9/L; B. Platelet count \< 75 x 10\^9/L; C. ALT or AST is 2 times higher than the uppe…